Cancer-germline genes in both humans and mice have been shown to encode antigens susceptible to targeting by cytotoxic CD8 T effector cells (CTL). We analysed the ability of CTL to kill different tumour cell lines expressing the same cancer-germline gene P1A (Trap1a). We previously demonstrated that CTL expressing a T-cell receptor specific for the P1A 35-43 peptide associated with H-2L d , although able to induce regression of P1A-expressing P815 mastocytoma cells, were much less effective against P1A-expressing melanoma cells. Here, we analysed parameters of the in vitro interaction between P1A-specific CTL and mastocytoma or melanoma cells expressing similar levels of the P1A gene and of surface H-2L d . The mastocytoma cells were more sensitive to cytolysis than the melanoma cells in vitro. Analysis by video-microscopy of early events required for target cell killing showed that similar patterns of increase in cytoplasmic Ca 2+ concentration ([Ca 2+ ]i) were induced by both types of P1A-expressing tumour cells. However, the use of CTL expressing a fluorescent granzyme B (GZMB-Tom) showed a delay in the migration of cytotoxic granules to the tumour interaction site, as well as a partially deficient GZMB-Tom exocytosis in response to the melanoma cells. Among surface molecules possibly affecting tumour-CTL interactions, the mastocytoma cells were found to express intercellular adhesion molecule-1, the ligand for LFA-1, which was not detected on the melanoma cells.
Introduction
CD8 T cells specific for melanoma tumour-associated antigens expressed as MHC class I-bound peptides have been detected in most melanoma patients. These cells, however, were generally unable to control tumour development (reviewed in ref. 1) . The inefficiency of tumour antigen-specific T cells developing in cancer patients has been attributed to: (i) their inefficient differentiation into effector cells; (ii) immune control mechanisms intrinsic to the T cells or dependent on regulatory T cells, the latter being relieved by antibody reagents targeting proteins involved in 'immune checkpoint controls'; and (iii) the tumour environment being conducive to 'exhaustion' of the T cells and producing immunomodulatory/immunosuppressive cytokines. Treatments with monoclonal antibodies (mAb) blocking the engagement of T-cell-expressed inhibitory receptors such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) were recently reported to provide longterm clinical benefit for some cancer patients, emphasizing the potential role of the immune system in tumour eradication. [2] [3] [4] Furthermore, the increase in the frequency and diversity of tumour-specific CD8 T cells in anti-CTLA-4 mAb-treated patients 5 and the observed proliferation of intra-tumoral CD8 T cells in patients that responded to anti-PD-1 ligand mAb treatment 6 underline the importance of CD8 T cells as anti-tumour effector cells in humans. Regardless of the type of therapy administered, a favourable prognosis was also found associated with the presence of cytotoxic T cells and expression of transcripts associated with cytolytic function (i.e. perforin, granzymes) in patients' primary tumours. 7 The effector functions of differentiated CD8 T cells include their capacity to kill target cells through the release of cytolytic granules at the immune synapse (reviewed in ref. 8) . Indeed, when optimally stimulated, CD8 T cells acquire the expression of exocytic granules belonging to the lysosome family, which contain the cytolytic enzymes perforin and granzymes. The different steps involved in the process of tumour cell killing have been clearly identified. Hence, on recognition of target cells via the T-cell receptor (TCR), cytotoxic granules are anchored to microtubules and migrate towards the immune synapse, together with the microtubule organizing centre. Polarized cytotoxic granules then fuse with the cell membrane, which leads to the release of the granule content (including perforin and granzymes) in the synaptic cleft. 9 The released perforin forms calcium-dependent pores in the target cell membrane. This allows for granzymes to access the target cell cytoplasm and induce cell death either directly (reviewed in ref. 8) or after their endocytosis following a membrane repair response in the target cell. 10 Although the mechanistic details of CTL activation leading to exocytosis of lytic granules have been extensively described, 11, 12 the molecular basis for the resistance of some tumour cells to CTL-mediated killing is less clear.
Calcium ion signals crucially control functional T-lymphocyte differentiation and activation. 13 They are initiated by engagement of the TCR, which results in activation of phospholipase Cc, production of inositol 1,4,5-trisphosphate and diacylglycerol. In turn the inositol 1,4,5-trisphosphate causes the release of Ca 2+ from the endoplasmic reticulum stores and leads thereby to the activation of Ca 2+ release-activated Ca 2+ (CRAC) channels and extracellular Ca 2+ entry into the cytoplasm (reviewed in ref. 14) . Store-operated Ca 2+ entry (SOCE) is required for cytolysis by CD8 T cells and, in particular, for TCR-induced lytic granule exocytosis. 15 Additionally, L-type calcium channels have also been implicated in the development of cytolytic effector cells. 16 We analysed the efficiency of CD8 T effector cells to kill different tumour cell lines expressing the same cancer-germline gene P1A (Trap1a). We previously demonstrated that CD8 T effector cells expressing a TCRspecific for the P1A [35] [36] [37] [38] [39] [40] [41] [42] [43] peptide (TCRP1A) associated with H-2L d that are able to induce regression of P1A-expressing mastocytoma P815 cells, 17 were much less efficient against P1A-expressing melanoma cells. 18, 19 Here, we analysed parameters of the in vitro interaction between P1A-specific TCRP1A CD8 T effector cells and mastocytoma or melanoma cells expressing similar levels of the P1A gene and of surface H-2L d . We previously generated knock in (KI) mice expressing Granzyme B (GZMB) as a fusion protein with red fluorescent tdTomato (GZMBTom). 20 Using these mice, we here derived P1A-specific TCRP1A CD8 T effector cells (CTL) expressing GZMBTom and monitored the early events of CTL activation by video-microscopy. These events were measured by changes in [Ca 2+ ]i followed by the re-localization of granules containing the fluorescent GZMB-Tom upon CTL interaction with distinct P1A-expressing tumour target cells.
Material and methods

Mice
Mice (Gzmb-Tom) genetically modified by homologous recombination to express GZMB-Tomato instead of GZMB have been described 20 and are registered as (EM:05732) at EMMA http://strains.emmanet.org/mutant_ types.php#keyword=5732.
For this study, Gzmb-Tom mice were crossed with TCRP1A mice that express as a transgene the H-2L d / P1A [35] [36] [37] [38] [39] [40] [41] [42] [43] -specific TCR on the Rag-1 À/À B10.D2 background. 21 The derived TCRP1A Rag-1 À/À B10.D2 mice expressing GZMB-Tom are designated as TCRP1A-GZMB-Tom. All mice were kept at the CIML animal facility in specific pathogen-free conditions. Mouse genotyping was performed by PCR as described previously.
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Mice and ethics statement
All procedures were approved by the Regional 'ProvenceAlpes-Cote d'Azur' Committee on Ethics for Animal Experimentation (authorization: no 13.521, date: 08/10/ 2012) and were in accordance with French and European directives. All efforts were made to minimize animal suffering.
Cell lines
Melanoma cell lines were derived from either TiRP (TyriRas-P1A-transgenic Ink4a/Arf flox/flox ) mice 22 kept on the B10.D2 background 18 (line T-1236) or TiRP-RFP mice (line T-RFP-69) 23 obtained after crossing TiRP B10.D2 mice with a Cre-reporter mouse expressing a tandemdimer red fluorescent protein (RFP). 24 Melanoma cells cultured in RPMI-1640 complete medium (10% fetal calf serum, antibiotics, glutamine 2 mM, 2-mercaptoethanol 50 µM) were collected before confluence after one wash with PBS followed by treatment with PBS, EDTA Trypsin (Gibco) for 5 min at 37°and one wash in RPMI-1640 culture medium. P1A-positive (P815 subline) mastocytoma P511 and its P1A-negative variant P1.204 obtained from Dr B. Van den Eynde (Ludwig Institute for Cancer Research, Brussels, Belgium) 25 were cultured in RPMI-1640 complete medium.
Quantitative RT-PCR
Quantitative RT-PCR for expression of endogenous P1A (Trap1a) and for the TiRP transgene-encoded HRas G12V and P1A (Trap1a) transcripts in melanoma cell lines was performed as previously described (see Supplementary methods in refs 18,23).
T-cell activation and differentiation
CD8 T cells from lymph nodes and spleen of TCRP1A-Gzmb-Tom mice were purified by negative selection. They were activated in 24-well culture plates (10 5 final). After 3 days in culture during which TCRP1A CD8 T cells divide and differentiate into CTL, T cells were further expanded in the presence of interleukin-2 (IL-2; murine IL-2 at 10 4 units/ml or human IL-2 at 10 5 units/ ml) and were used within 1 week.
T-cell analysis
FACS analysis on live or fixed and permeabilized cells, labelling with Cell Tracer Violet (CTV; Molecular Probes, Eugene, OR) to follow cell division, measure of degranulation using anti-Lamp1-APC mAb, Fluo-4 acetoxymethylester (Molecular Probes) labelling to measure Ca 2+ flux, and video microscopy analyses were as previously described. 20 When indicated, tumour target cells were pre-loaded with calcein violet acetoxymethylester (1 µM final; Molecular Probes) or CTV (2Á5 µM final). For video-microscopy using adherent melanoma cells as target cells, eight-well plates (Lab-Tek chamber slides, NUNC) were seeded with the tumour cells to be used before full confluence.
Video analyses
Time-lapse analysis was performed using a Zeiss780 confocal microscope (409/0Á7 NA oil immersion objective) as described previously. 20 Images were analysed with the FIJI software. The complete videos were analysed by the recently described METHODS FOR AUTOMATED AND ACCURATE ANALYSIS OF CELL SIGNALS (MAAACS) software. 26 Briefly, the software allowed the automated tracking and analysis of the calcium response of each individual cell. The fluorescence intensity was normalized to the median of the values of signal intensity of each CTL. Thresholding was determined with the aim of maximizing the detection of truly activated cells while minimizing the probability of false alarm, as described elsewhere. 26 The fluorescence amplitude (FA) threshold was set to a value of 2Á5 in combination with a response fraction threshold of 0Á1 (RF; time fraction where fluorescence signal is greater than the FA threshold) to classify calcium response types (sustained: FA > 2Á5 and RF > 0Á6; oscillating: FA > 2Á5 and 0Á2 < RF < 0Á6, unique: FA > 2Á5, RF < 0Á2 and a single burst).
Results
Characteristics of tumour cell lines expressing the P1A tumour antigen Mastocytoma cell line P511 and melanoma lines established from TiRP mice express transcripts encoded by the endogenous P1A gene (P511) or by the transgene construct in the melanoma lines (T-1236 and T-RFP-69) (see Supplementary material, Fig. S1a ). In agreement with our previous findings 18, 23 TiRP-derived melanoma lines generally express similar (here line T-1236) or higher (here line T-RFP-69) P1A transcript levels than P511 mastocytoma cells. As expected, 27 no P1A transcripts were detected in the mastocytoma antigen-loss variant P1.204 (see Supplementary material, Fig. S1a ). In Fig. 1 we determine the level of surface expression of some of the markers of the tumour lines that may be important for immunogenicity and T-cell activation. H-2L d is highly expressed on the mastocytoma cells P511 and P1.204, as well as on the T-1236 melanoma line ( Fig. 1 and results not shown), whereas it is not detectable on the surface of melanoma line T-RFP-69 (Fig. 1) . 23 The CD28 ligand B7-1 (CD80) was not expressed on the mastocytoma cells, whereas it was highly expressed on T-1236 and on part of the T-RFP-69 melanoma cells. The LFA-1 adhesion ligand intercellular cell adhesion molecule 1 (ICAM-1), on the other hand, was highly expressed on the mastocytoma cells but very poorly expressed on the melanoma lines.
As previously shown, 17,28 TCRP1A CD8 T effector cells were efficient at killing specifically the P1A-expressing P511 target cells, but not the P1A-deficient P1. Upon further divisions of the T cells after 72 hr, the levels of expression of CD25 as well as of GZMB-Tom decreased and no IL-2 production was detected. This pattern is consistent with that observed for stimulation of naive CD8 T cells with a weak agonist, a condition in which IL-2 production is limiting. 29 Indeed, signalling through the IL-2 receptor is required for sustained expression of CD25 as well as GZMB. 29 Accordingly, addition of IL-2 at day 3 to the peptide-stimulated TCRP1A-Gzmb-Tom CD8 T cells allowed for a sustained expression of GZMB-Tom. This mode of stimulation was used to generate TCRP1A-Gzmb-Tom CTL to be used in the following sections (see Material and Methods).
CTL degranulation induced by different tumour cells
We next measured the capacities of the different tumour cells to induce degranulation of the TCRP1A-GZMB-Tom CTL. CTL degranulation can be monitored by the resulting exposure of Lamp-1 that is measured by anti-Lamp-1 mAb binding. 30 Cytolytic granule exocytosis can also be measured here by the decrease of GZMB-Tom red fluorescence from CTL. 20, 31 Resting CTL ( (Fig. 3a,b) . Pre-incubation of tumour cells with P1Ap slightly increased CTL degranulation whether measured by increase in Lamp1 detection or decrease in GZMB-Tom fluorescence for the P511 tumour cells, whereas for P1.204 tumour cells, which did not induce degranulation in the absence of added peptide, a clear increase in antiLamp1 and decrease in GZMB-Tom fluorescence was observed. For T-1236 cells, P1Ap pre-incubation led to an increase in anti-Lamp1 fluorescence and to detection of a decrease in GZMB-Tom fluorescence. For T-RFP-69 cells peptide pre-incubation also led to previously undetected increase in anti-Lamp1 fluorescence but no significant decrease in GZMB-Tom was observed (Fig. 3a,b) .
These results suggest that the availability of the relevant peptide-MHC complexes on melanoma cells may be limiting the CTL response. Melanoma cells expressing high levels of surface H-2L d could induce some CTL exocytosis as measured by Lamp1 staining, albeit sub-optimally and without detectable loss in GZMB-Tom expression in the absence of exogenous peptide addition. For melanoma cells expressing low levels of surface H-2L d , exogenous peptide addition was mandatory.
Time-lapse live microscopy of early activation events induced by different P1A-expressing tumours in TCRP1A-GZMB-Tom CTL.
To monitor early changes in [Ca 2+ ]i induced by tumour cells in TCRP1A-GZMB-Tom CTL by video microscopy, the CTL were loaded with the [Ca 2+ ]i sensitive fluorescent dye Fluo-4, the intensity of which is represented in false colours in Fig. 4(a,b) (upper lanes), whereas GZMBTom containing granules visualized in red (Fig. 4a,b , upper and lower lanes) can be clearly observed when Fluo-4 fluorescence is deleted (Fig. 4a,b, lower lanes) . The P511 and P1.204 mastocytoma target cells were preloaded with Calcein Violet-AM to detect dye leakage upon damage to the target plasma membrane (Fig. 4a) .
One representative sequence of events ( Fig. 4a ; and see Supplementary material, Video S1) shows that the contact (time 0) of TCRP1A-GZMB-Tom CTL with P1A-expressing mastocytoma P511 induces an important [Ca 2+ ]i (sustained from 2 to 40 min after cell contact) associated with a change in the CTL shape and formation of an immune synapse, leading to massive re-localization of red GZMB-Tom granules to the contact zone (starting 6 min after the [Ca 2+ ]i burst - cells, no granule re-localization occurred in the CTL and no calcein leakage from the tumour was observed (Fig. 4a) . A transient [Ca 2+ ]i was occasionally observed (see later section - Fig. 5 ). Melanoma cells T-1236 were labelled with CTV because these tumour cells failed to take up Calcein Violet. The representative sequence of events (Fig. 4b, and (Fig. 4b) . When pre-pulsed with P1Ap, however, the T-RFP-69 melanoma cells induced CTL activation with an increase in [Ca 2+ ]i, a change in cell shape and re-localization of a few granules at the CTL-target contact zone (at time 9 min 50 seconds - Fig. 4b , and see Supplementary material, Video S3).
As diverse patterns of [Ca 2+ ]i appeared to be induced in the CTL by the different tumour cells, we used a software, MAAACS, established in the laboratory 26 to sort these patterns in detail for a number of CTL-tumour cell conjugates (Fig. 5) As the plating efficiency of the melanoma cells (plasticadherent cells) was generally higher than that of the nonadherent mastocytoma cells, the chances for a CTL to interact with a target cell was higher for the melanoma compared with mastocytoma cells. Therefore the comparison of the fraction of responding CTL is probably underestimated for the mastocytoma compared with the melanoma cells. We think therefore that the frequency of CTL activated with a given type of [Ca 2+ ]i response (sustained versus oscillating) is a more important parameter than the frequency of responding CTL in the comparison between melanoma and mastocytoma cells.
The analysis shows that mastocytoma cells P511 induce [Ca 2+ ]i changes in 56% of the CTL, of which 38% presented a sustained response, 59% an oscillating response and 3% a unique transient response (Fig. 5a,b) . The amplitude of the response could reach a 10-to 25-fold increase, but was around fivefold on average (Fig. 5c ) with a fraction response around 0Á55 on average (Fig. 5d) . By comparison, the P1A-negative P1.204 mastocytoma cells induced a weak amplitude response (Fig. 5c) in 13% of the CTL mostly of the oscillating type with no sustained response (Fig. 5a,b) and a very low fraction response (Fig. 5d) . In these conditions no granule re-localization was observed.
Melanoma cells T-1236 induced a [Ca 2+ ]i increase in 79% of the CTL, 44% of which presented a sustained response, whereas 56% presented an oscillating response (Fig. 5a,b) . The mean amplitude of the response and the fraction response were in the same range as those induced by the P511 cells (Fig. 5c,d ). It should be noted that no saturation of the Fluo-4 signal was observed for the highest amplitude responses to either P511 or T-1236 (see Supplementary material, Fig. S3 ). The H-2L d low T-RFP-69 melanoma cells induced responses of low amplitude and fraction time in 16% of the CTL with 81% being oscillating and 19% sustained (Fig. 5a-d) . Although of similar low amplitude as the response to the P1A-negative mastocytoma cells, the H-2 low melanoma cells elicited some 'sustained' [Ca 2+ ]i responses, as also indicated by their slightly higher fraction response (Fig. 5d) . When T-RFP-69 melanoma cells were pre-incubated with P1Ap, 38% of the CTL responded, 37% of them with a 'sustained' profile and 63% with an oscillating profile (Fig. 5a,b) . The mean amplitude and fraction responses were slightly, but not statistically significantly, increased compared with those induced in the absence of P1Ap (Fig. 5c,d ). This result suggests that even with low MHC expression on the melanoma cells, addition of exogenous cognate peptide may lead to sufficient relevant peptide-MHC complexes to allow activation with a sustained [Ca 2+ ]i response of a fraction of the CTL. In conclusion, we described different behaviours of the same CTL specific for a tumour antigen expressed in different tumour cell lines. P1A-expressing mastocytoma cells were able to efficiently activate the TCRP1A CTL, leading to granule exocytosis and target cell lysis. TCRP1A CTL activation by the P1A-expressing melanoma cells was less efficient, even for the H-2L d high T-1236 tumour cells, which induced activation up to relocalization of the granules to the target contact zone, but in which no lethal hit was observed. The lower efficiency for induction of cytolysis by the melanoma as compared to the mastocytoma cells occurred in spite of their similar induction of sustained [ Comparison of the patterns of early activation events of P1A-tumour antigen reactive TCRP1A CTL with those of OT1 CTL optimally stimulated by peptide OVAp
To evaluate how the early activation events of CTL directed at the P1A-encoded cancer-germline antigen compare with the optimal simulation described for the OT1 CD8 T cells/OVAp model, MAAACS analysis was applied to our previously reported time-lapse live microscopy experiments of OT1 GZMB-Tom CTL interacting with either OVAp-pulsed RMA-S thymoma cells or with EL4 thymoma expressing the OVA gene (EG7) whereas RMA-S cells pulsed with an irrelevant H-2K b binding peptide (pKB1) were used as a control. 20 Data (see Supplementary material, Fig. S4 and Table S1A) report that the OT1 response to OVAp/RMA-S or to EG7 cells was of similar amplitude as the TCRP1A response to P511 or to T-1236. However, a higher proportion of the OT1 cells presented a sustained [Ca 2+ ]i rise (64% and 73%, respectively against OVAp/RMA-S and EG7 target cells). Altogether, the frequency of [Ca 2+ ]i bursts was much lower in the OT1 compared with the TCRP1A response (see Supplementary material, Fig. S6 ). When comparing data for degranulation (see Supplementary material, Table S1B), it was found that 90% of the OT1 cells expressed Lamp-1 and a 66% decrease in GzmB-Tom MFI was observed in response to RMA-S/OVAp. Hence a sustained [Ca 2+ ]i response for a higher proportion of the CTL and a more extensive degranulation as measured by either Lamp-1 exposure or loss of GzmB appear to characterize the OT1 response to OVAp. This was associated with granule relocalization to the target cell after about 5 min (similar to the response of TCRP1A CTL to P511) but led to a measurable target hit (calcein release) within < 15 min for all CTL observed (see Supplementary material, Fig. S5 , Table S1A ). In comparison only about half of the P511 target cells leaked calcein (see Supplementary material, Fig. S2 , Table S1A ). The high affinity OT1 TCR/OVAp led to a sustained [Ca 2+ ]i rise correlated with GzmB exocytosis in a majority of the CTL, resulting in calcein release from all hit target cells.
Discussion
To optimize immunotherapies against neoplasms, it is important to understand to which effector mechanisms a particular tumour is sensitive or resistant. These characteristics may differ depending on the expressed tumour antigens (qualitative/quantitative) and degree of MHC expression, as well as on the level of expression of ligands for adhesion receptors (LFA-1) or co-stimulatory or inhibitory receptors (such as PD-1). Parameters that affect the efficiency of adoptive CD8 T-cell therapy in pre-clinical models include the capacity of the transferred T cells to infiltrate the tumour 34 and to survive in the tumour microenvironment 35, 36 as well as extended proliferative capacity of the T cells. 37, 38 Although a correlation has been observed between the affinity of TCR/tumour antigen-MHC interaction and efficiency in adoptive T-cell therapy, 36 it is not clear which parameters affect the differential capacity of CD8 T effector cells to induce regression of tumour cells through the same TCR/tumour antigen-MHC interaction.
Here, we analysed how tumour cells of distinct origin expressing the same cancer-germline antigen are differentially sensitive to tumour antigen-specific CTL obtained by in vitro stimulation with peptide antigen. The P1A-encoded tumour antigen to which partial CD8 T-cell ]i response to the melanoma compared with the mastocytoma cells. Previous reports pointed to the unique role for the LFA-1/ICAM-1 interaction as providing co-activation to CD3/TCR-mediated lysis by CTL through both an enhanced CTL-target cell binding 45 and the delivery of post-conjugate co-stimulatory signals. 46, 47 It should be noted that the response to both P1A-expressing mastocytoma and melanoma cells contrasted with the 'optimal' response of OT1 CTL to OVAp on EL4 tumour cells that was mostly of the sustained type. This difference is possibly to be attributed to the lower strength of TCR signalling in the P1A compared with the OVAp models. In the latter case it was shown that the strength of engagement of the OT1 TCR (by altered peptide G4 instead of OVA 257-264 ) controlled the recruitment of the cytotoxic granules to the immune synapse, although centrosome polarization was not affected. 33 In this example, however, the interaction of the TCR with the altered G4 peptide was of such low avidity that it failed to induce any [Ca 2+ ]i response. Table S1 ). Tumour-induced re-localization of cytolytic granules toward the CTL-target cell contact zone occurred in response to both P1A-expressing mastocytoma and melanoma cells. The kinetics of this process were much delayed, however, for melanoma compared with mastocytoma cells. The next steps involving the fusion of cytolytic granules with the plasma membrane and the exocytosis leading to the release of cytolytic enzymes appeared to take place in response to both mastocytoma and melanoma cells, although less efficiently in the latter case. In particular, while degranulation induced by the mastocytoma cells could be measured by either the exposure of Lamp1 or by the decrease in GZMB-Tom content in the CTL, the latter event was not detected upon interaction of the CTL with the melanoma cells. Finally, although the lethal hit in the mastocytoma cells could be visualized, this was not the case for the melanoma cells, an observation in line with the poor 51 Crrelease observed in classical 4-hr CTL assays.
At this point we are unable to formally discriminate whether the CTL granule content was not delivered efficiently to the melanoma cells or whether the melanoma cells presented an intrinsic resistance to the cytolytic effectors. Relevant to the first possibility, it has been suggested that LFA-1 may deliver a distinct signal essential for directing released cytolytic granules to the surface of target cells to mediate lysis. 49 The nature of this potential signal has not been defined, however, and it is not clear whether lack of the ICAM-1 ligand on the melanoma target cell may contribute to such a defective delivery. Other data lend support to the second, not exclusive possibility. Notably, a study on human melanoma cells 50 showed that ICAM-1-negative melanoma cells could induce cytolytic granule polarization as well as ICAM-1-expressing melanomas, but failed to be killed by the same CTL. The authors further observed that the level of ICAM-1 expression by melanoma cells correlated positively with decreased phosphatase and tensin homolog (PTEN) activity and decreased activity of the PI3K/AKT pathway, suggesting that low expression of ICAM-1 was intrinsically associated with the activation of a survival pathway. 50 In another study comparing the efficiency of the same human CTL effector cells on tumour target cells from different tissue origins, it was concluded that melanoma cells were intrinsically more resistant than 'classically' used Epstein-Barr virus-transformed B-cell lines to killing via cytolytic granule delivery. 51 In that study, the kinetics of CTL activation, polarization of cytolytic granules and lethal hit delivery appeared similar for the two types of tumours. However, repetitive hits from the CTL appeared to be required to achieve melanoma cell destruction. The status of ICAM-1 expression by the tumour cells was not discussed in that study and fine differences in the pattern of CTL activation (as observed in our study) may have been bypassed due to use of high concentrations of exogenous antigenic peptide. 51 More recently, this group identified a defence mechanism of human melanoma cells based on their exacerbated lysosome secretion and cathepsin B-mediated perforin degradation at the lytic synapse. 52 Over-expression of serpin-9 (gene PI-9), an inhibitor of GzmB activity, has also been described in metastatic melanoma. However, its depletion did not enhance the melanoma susceptibility to CTL killing. 50 Whether LFA-1/ICAM-1 interactions may affect the exocytosis step is still to be determined. Indeed, a recent report suggests that cytolytic secretory events occur in an intermediate domain that overlaps with the region of strongest force exertion. 53 In the 'Immune Synapse' (IS), this zone is occupied by the clusters of integrins (LFA-1) 54 corresponding to the adhesive and cytoskeletal machinery required to transmit force. The authors favour a model in which degranulation occurs at the border between the IS central F-actin-depleted area and the peripheral F-actin ring (LFA-1). This would balance the physical requirements of exocytosis (actin hypodense region of the plasma membrane suitable for vesicle fusion and granule secretion 12 ) and synaptic mechanopotentiation provided by the integrin-associated cytoskeletal machinery. 53 Consistent with the low number of peptide-MHC complexes on target cells required to activate CTL, 55 58, 59 It will therefore be important to further establish which parameters (strength of TCR engagement/co-stimulatory receptors) affect the regulation of Ca 2+ -channel functioning in CTL and how this impacts on the various steps of granule dynamics and exocytosis. It is not clear at this point whether the observed difference in killing efficiency by TCRP1A effector cells of mastocytoma versus melanoma tumour cells is responsible for the difference in tumour regression observed in vivo upon transfer of TCRP1A effector cells in tumour-bearing mice. 19 Additional mechanisms independent of GzmB/ perforin, such as those mediated by TnfSF molecules like Fas-ligand may be involved in tumour cell killing in vivo. No significant Fas-mediated killing was detected in in vitro stimulated TCRP1A effector cells, however. 60 Tumour regression may also derive from indirect actions by CTL-secreted cytokines such as interferon-c that exert angiostatic effects, 61 and can promote stroma destruction. 62 CTL-initiated cytokine-mediated activation of innate-type effectors within the tumour microenvironment may also contribute to tumour regression. 17 Together with available data from the literature, 50, 63 our study suggests that lack of ICAM-1 expression by tumour cells may represent an unfavourable factor for potential use of adoptive immunotherapy using killer cells unless the T cells are engineered to present heightened effector functions 19 or to express an affinity-enhanced TCR against the tumour antigen. 36 Use of the GZMB-Tom CTL would further be of interest -to establish whether LFA-1 engagement may contribute to improve the killing process of melanoma cells by CTL (comparing melanoma cells expressing or not ICAM-1) and decipher the step at which this may occur and whether a correlative change in the dynamics of granule re-localization and exocytosis of GzmB would be observed -to observe the respective effects of enhanced CTL effector function or TCR affinity on the killing process -and finally to monitor the killing events within the tumour microenvironment in vivo. data and discussion. PM developed the GzmB-Tom mice. GV and MB established the melanoma lines, MFa helped with the video microscopy and YH and CBi helped with Ca 2+ signalling data analyses. CBo and AMSV wrote the paper.
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